RECURRENT PLATINUM-RESISTANT OVARIAN CARCINOMA
Clinical trials for RECURRENT PLATINUM-RESISTANT OVARIAN CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new RECURRENT PLATINUM-RESISTANT OVARIAN CARCINOMA trials appear
Sign up with your email to follow new studies for RECURRENT PLATINUM-RESISTANT OVARIAN CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New drug cocktail aims to shrink ovarian tumors in recurrent cancer
Disease control Recruiting nowThis study tests whether adding an experimental drug (CDX-1140) to a standard immunotherapy combo (pembrolizumab and bevacizumab) can shrink tumors in people with ovarian cancer that has returned. About 80 adults with recurrent ovarian, fallopian tube, or peritoneal cancer will r…
Matched conditions: RECURRENT PLATINUM-RESISTANT OVARIAN CARCINOMA
Phase: PHASE2 • Sponsor: Roswell Park Cancer Institute • Aim: Disease control
Last updated May 26, 2026 03:44 UTC
-
New drug combo targets tough ovarian cancer
Disease control Recruiting nowThis early-phase trial tests two drugs, abemaciclib and olaparib, together in people with ovarian cancer that has stopped responding to platinum-based chemotherapy. The main goals are to find the safest dose and see if the combination can shrink tumors. About 42 participants will…
Matched conditions: RECURRENT PLATINUM-RESISTANT OVARIAN CARCINOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 26, 2026 03:44 UTC
-
New drug combo aims to tackle Hard-to-Treat ovarian cancer
Disease control Recruiting nowThis early-phase study tests a new drug, DT2216, combined with the chemotherapy paclitaxel in people whose ovarian cancer has returned and is resistant to platinum-based treatments. The main goal is to find the safest dose of DT2216 when given with paclitaxel. About 30 participan…
Matched conditions: RECURRENT PLATINUM-RESISTANT OVARIAN CARCINOMA
Phase: PHASE1 • Sponsor: Elizabeth Stover, MD, PhD • Aim: Disease control
Last updated May 26, 2026 03:34 UTC
-
New drug combo targets Hard-to-Treat ovarian and endometrial cancers
Disease control Recruiting nowThis early-phase study tests two experimental drugs (M1774 and ZEN-3694) together in people whose ovarian or endometrial cancer has returned. The goal is to find the safest dose and see how well the combination works. About 65 participants will take part to help determine if this…
Matched conditions: RECURRENT PLATINUM-RESISTANT OVARIAN CARCINOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 22, 2026 14:04 UTC
-
Ovarian cancer Patients' own immune cells supercharged to fight tumors
Disease control Recruiting nowThis early-phase study tests a new treatment for ovarian cancer that has come back or not responded to standard therapy. Doctors take a patient's own immune cells (T cells), train them in a lab to recognize a protein called MUC1 found on cancer cells, and then give them back to t…
Matched conditions: RECURRENT PLATINUM-RESISTANT OVARIAN CARCINOMA
Phase: PHASE1 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated May 22, 2026 13:54 UTC